Eversept Partners LP lifted its holdings in shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 21.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 305,233 shares of the company’s stock after acquiring an additional 54,801 shares during the quarter. Deciphera Pharmaceuticals comprises approximately 2.0% of Eversept Partners LP’s holdings, making the stock its 13th biggest holding. Eversept Partners LP’s holdings in Deciphera Pharmaceuticals were worth $6,883,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new position in shares of Deciphera Pharmaceuticals during the 2nd quarter valued at $64,000. BlackRock Inc. lifted its holdings in Deciphera Pharmaceuticals by 25.6% in the 2nd quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock worth $34,543,000 after buying an additional 311,870 shares in the last quarter. Virtus ETF Advisers LLC lifted its holdings in Deciphera Pharmaceuticals by 17.7% in the 2nd quarter. Virtus ETF Advisers LLC now owns 12,449 shares of the company’s stock worth $281,000 after buying an additional 1,871 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in Deciphera Pharmaceuticals by 12.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 26,236 shares of the company’s stock worth $592,000 after buying an additional 2,922 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Deciphera Pharmaceuticals by 24.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,468 shares of the company’s stock worth $1,319,000 after buying an additional 11,342 shares in the last quarter. Institutional investors and hedge funds own 45.68% of the company’s stock.

Shares of DCPH traded up $0.38 during midday trading on Friday, hitting $36.86. The company had a trading volume of 1,103 shares, compared to its average volume of 1,088,560. The company’s 50 day moving average price is $30.99 and its 200 day moving average price is $25.60. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -13.07 and a beta of 1.92. Deciphera Pharmaceuticals Inc has a 52 week low of $18.55 and a 52 week high of $42.99. The company has a quick ratio of 7.26, a current ratio of 7.26 and a debt-to-equity ratio of 0.01.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.12) by $0.56. The company had revenue of $25.00 million during the quarter, compared to the consensus estimate of $20.00 million. Equities analysts anticipate that Deciphera Pharmaceuticals Inc will post -4.21 EPS for the current fiscal year.

In other news, Director Michael Douglas Taylor sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $36.26, for a total value of $271,950.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $271,950. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Thomas Patrick Kelly sold 11,250 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $41.27, for a total transaction of $464,287.50. The disclosure for this sale can be found here. Insiders sold a total of 539,534 shares of company stock valued at $20,465,526 in the last three months. Insiders own 7.02% of the company’s stock.

A number of equities analysts have commented on DCPH shares. BidaskClub upgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 16th. Guggenheim boosted their price objective on shares of Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Leerink Swann reiterated a “positive” rating and issued a $29.00 price objective (up previously from $20.00) on shares of Deciphera Pharmaceuticals in a report on Wednesday, August 14th. Piper Jaffray Companies boosted their price objective on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, June 3rd. They noted that the move was a valuation call. Finally, SunTrust Banks boosted their price objective on shares of Deciphera Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Deciphera Pharmaceuticals presently has an average rating of “Buy” and an average target price of $48.00.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Story: What Are Treasury Bonds?

Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH).

Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.